RESEARCH REPORT
Johnson & Johnson
JNJ
$273.20
As of 2026-11-01
Research note — 2026-11-01. Educational analysis, not financial advice.
The one-line version
Johnson & Johnson trades near $273.20 on a trailing multiple of about 41.5x versus its own 5-year median near 30.9x, against contested Street targets and the usual concentration and execution risks. That's the tension. Everything below is the detail.
That's the tension. Everything below is the detail.
1. What you're paying
| Now | Its own 5-year median | Gap | |
|---|---|---|---|
| P/E (trailing) | ~41.5 | ~30.9 | +34% |
| P/E (forward) | ~23.5 | — | — |
| EPS (TTM) | 6.59 | — | — |
| Gross margin | 67.8% | — | — |
What that means in plain terms: the gap versus the company's own history is the growth or durability the market is already pricing. It is not automatically wrong — it is the bet.
Fair-value anchors on file:
- 5-year median P/E multiple: $203.67 — Applies the 5-year median multiple (30.9x) to trailing EPS.
- Street mean target: $279.41 — Average published analyst target.
- Street target midpoint: $255.00 — Midpoint of $190.00–$320.00 published range.
Street targets run from $190.00 to $320.00. A wide spread means the name is contested, not consensus.
2. What the bulls are counting on
- Suze Orman Says You Don’t Have to transact in Every Market Dip. Here’s Why
- Roth IRA vs. Taxable Account: How Much of $17,985 in Blue-Chip Dividends Would You Keep?
- If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to Own
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
3. What the bears see
- 5 Dividend Stocks to transact in and neutral for the Next 5 Years
- 3 Biotech Stocks With Upside Of Up To 80%
- Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells market participants.
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
4. What would have to be true
For the stock to justify ~41.5x rather than its 5-year ~30.9x, roughly all of the following need to neutral:
- Growth or margin durability shows up in the next several reports, not just in narrative.
- Key revenue concentrations survive competitive and regulatory pressure.
- Execution on the current product or services cycle stays on schedule.
- The Street target range compresses as results clarify the contested assumptions.
Ask yourself honestly: how many of those would you bet on individually? Multiply your answers together.
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
5. What to watch next
- Next earnings date: 2027-01-26
- Trailing and forward multiples versus the company's own history
- Segment growth rates in the next 10-Q / earnings release
- Material Form 4 and 13F changes
- Whether the Street high-to-low target spread narrows or widens
Sign up free to read the full analysis
Bull case, bear case, assumptions, and what to watch next.
6. What this note does not do
It doesn't tell you to buy or sell. It won't, ever.
You have the valuation in context, the strongest version of both cases, and the specific assumptions the current price depends on. What you do with that depends on your time horizon, your existing exposure, your risk tolerance, and what else you could do with the money — none of which we know.
If you want someone to tell you what to do, you want a licensed financial adviser, and that is a genuinely reasonable thing to want.
Educational and informational purposes only. Not investment advice and not a recommendation to buy or sell any security. GetStockReport is not a registered investment adviser. Figures are as of 2026-11-01 and go stale quickly — verify against primary sources before acting. All investments carry risk including loss of principal. Past performance does not guarantee future results.
8. Analyst ratings & targets
No recent activity
Analyst opinions change frequently. Past upgrades do not predict future returns.
9. Important news
Nov 4, 2026|CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation Index(Yahoo)
Sanofi ranked first in the 2026 CNS Summit Digital Innovation Index, developed in collaboration with IDEA Pharma, a division of SAI MedPartners, placing in the top three in all three categories. The rankings were revealed today on the CNS Summit 2026 main stage at Encore Boston Harbor.
Nov 4, 2026|Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy(Yahoo)
Key TakeawaysZimmer Biomet shares jumped 15% after third-quarter sales grew 3. 7% in constant currency and it raised its 2026 guidance.
Nov 4, 2026|Moderna Soars 8% on Early Multiple Myeloma Data for Its Three-in-One mRNA Therapy(Yahoo)
Key TakeawaysModerna shares jumped 8% after its myeloma therapy, mRNA-2808, showed four confirmed responses among 11 heavily pretreated patients. The data shows Moderna’s mRNA can get the body to make three cancer drugs at once, though it’s years from challenging Johnson & Johnson, Pfizer and Regeneron.
Nov 4, 2026|Roth IRA vs. Taxable Account: How Much of $13,467 in Dividends Would You Keep?(Yahoo)
A $500,000 portfolio of six blue-chip dividend growers kicks off thousands in annual income, but where you hold those shares determines how much of that income you actually get to keep.
Nov 4, 2026|BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays Weak(Yahoo)
Boston Scientific's cyber disruption cuts Q3 growth and earnings, forcing lower 2026 guidance as management sees 2027 as the cycle's trough.
News headlines are reported as-is. Verify important claims with original sources.
10. Insider Form 4 activity
No recent activity
Form 4 filings are routine transactions. Scheduled sales (10b5-1 plans) are normal and not signals.
11. Institutional 13F holdings
| Fund | Shares | Position | Change |
|---|---|---|---|
| Vanguard Group | 216,514,970 | $44.8B | — |
| State Street | 133,776,025 | $34.0B | — |
| BlackRock | 74,807,981 | $10.9B | — |
| BlackRock Institutional Trust | 5,835,154 | $672.3M | — |
These are 45-day lagged filings (SEC requirement). Position changes happened in the past.
12. Earnings this week
No recent activity
Earnings dates are estimates and may shift. EPS estimates are consensus, not predictions.